1.
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour act...
by Wilson, Wyndham H, Prof
The lancet oncology, 2010, Vol.11 (12), p.1149-1159
2.
Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects ‐ a randomised open‐label cross‐over study...
by Sakurai, Y.
Alimentary pharmacology & therapeutics, 2015, Vol.42 (6), p.719-730
3.
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK‐438 (vonoprazan), a novel potassium‐competitive acid blocker, in hea...
by Jenkins, H.
Alimentary pharmacology & therapeutics, 2015, Vol.41 (7), p.636-648
4.
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
by Matucci-Cerinic, Marco
Annals of the rheumatic diseases, 2011, Vol.70 (1), p.32-38
5.
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
by McArthur, Grant A
The lancet oncology, 2014, Vol.15 (3), p.323
6.
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial
by Martin-Broto, Javier
The lancet oncology, 2019, Vol.20 (1), p.134-144
7.
Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype
by Kagami, T.
Alimentary pharmacology & therapeutics, 2016, Vol.43 (10), p.1048-1059
8.
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: An open-label, multicentre, safety study
by Larkin, James
The lancet oncology, 2014, Vol.15 (4), p.436-444
9.
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRA...
by Grob, Jean Jacques, Prof
The lancet oncology, 2015, Vol.16 (13), p.1389-1398
10.
A selective BCL-X L PROTAC degrader achieves safe and potent antitumor activity
by Khan, Sajid
Nature medicine, 2019, Vol.25 (12), p.1938
11.
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
by Dummer, Reinhard
The lancet oncology, 2018, Vol.19 (5), p.603-615
12.
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, p...
by Dummer, Reinhard
The lancet oncology, 2018, Vol.19 (10), p.1315-1327
13.
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multi...
by Forns, Xavier
The Lancet infectious diseases, 2017, Vol.17 (10), p.1062-1068
14.
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis
by Chayama, Kazuaki
Journal of gastroenterology, 2017, Vol.53 (4), p.557-565
15.
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomise...
by Clotet, Bonaventura, Dr
The Lancet (British edition), 2007, Vol.369 (9568), p.1169-1178
16.
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double...
by Jacobson, Ira M, Prof
The Lancet (British edition), 2014, Vol.384 (9941), p.403-413
17.
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
by Chang, Jianhui
Nature medicine, 2016, Vol.22 (1), p.78-83
18.
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
by Necchi, Andrea, Dr
The lancet oncology, 2012, Vol.13 (8), p.810-816
19.
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b stud...
by Clotet, Bonaventura, Dr
The Lancet (British edition), 2014, Vol.383 (9936), p.2222-2231
20.
A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer
by Bible, Keith C
The journal of clinical endocrinology and metabolism, 2012, Vol.97 (9), p.3179-3184
